

Theme	Session Title	Presentation No.	Abstract No.	Lecture title	Speaker	Country
Tumor-type specific Sessions	Ependymoma (basic)	EPEB-IS-01	SPKR-30	Ependymoma, an increasingly less enigmatic disease	Kristian Pajtler	Germany
		EPEB-O-02	EPEN-04	Oncogenic 3D tumor genome organization identifies new therapeutic targets in ependymoma	Lukas Chavez	USA
		EPEB-O-03	EPEN-31	Single-cell RNAseq of childhood ependymoma reveals distinct neoplastic cell subpopulations that impact etiology, molecular classification and outcome	Andrew Donson	USA
		EPEB-O-04	EPEN-18	Cross-species genomics identifies GLI2 as an oncogene of C11orf95 fusion-positive supratentorial ependymoma	Tuyu Zheng	Germany
		EPEB-O-05	EPEN-41	C11orf95-RELA fusion regulates aberrant gene expression through the unique genomic binding sites for ependymoma formation	Tatsuya Ozawa	Japan
		EPEB-O-06	EPEN-52	Metabolic regulation of the epigenome drives lethal infantile ependymoma	Sachin Kumar	Canada
		EPEB-P-07	EPEN-30	C11ORF95-RELA fusion protein engages novel genomic loci to drive murine ependymoma growth	Stephen Mack	USA
		EPEB-P-08	EPEN-43	Targeting intra-tumour heterogeneity in paediatric ependymoma: an integrated omics study towards patient-tailored therapy	Alina Pande	UK
		EPEB-P-09	EPEN-20	EZH1/CATACOMB cooperates with PDGF-A and p53 loss to generate a genetically engineered mouse model for posterior fossa A ependymoma	Emily Kagan	USA
		EPEB-P-10	EPEN-21	Impaired neuronal-glia fate specification in pediatric ependymoma revealed by single-cell RNA-Seq	Bernhard Engliger	USA
		EPEB-P-11	EPEN-16	Transcriptional regulatory circuitries as molecular targets in ependymoma	Kelsey Bertrand	USA
		EPEB-P-12	EPEN-22	Single-cell RNA sequencing identifies upregulation of IKZF1 in PFA2 myeloid subpopulation driving an anti-tumor phenotype	Andrea Griesinger	USA
		EPEB-P-13	EPEN-42	Molecular profiling reveals distinct subgroups of pediatric spinal ependymoma	Anbarasu Lourdasamy	UK
		EPEB-P-14	EPEN-27	CDKN2A deletion in supratentorial ependymoma with RELA alteration indicates a dismal prognosis – a retrospective analysis of the HIT ependymoma trial cohort	Torsten Pietsch	Germany
		EPEB-P-15	EPEN-33	Pharmacogenomics reveals synergistic inhibition of ERBB2 and PI3K signaling as a therapeutic strategy for ependymoma.	David Pauck	Germany
		EPEB-P-16	EPEN-23	A computational analysis of the tumour immune microenvironment in paediatric ependymoma	Timothy Ritzmann	UK
		EPEB-P-17	EPEN-26	Non-canonical NF-κB signaling drives mesenchymal ependymal cell subpopulation in PFA ependymoma	Andrea Griesinger	USA
		EPEB-P-18	EPEN-34	The CRISPR-Cas9 system-mediated endogenous gene rearrangement induced C11orf95-RELA fusion in vitro and in vivo that led to the development of ependymoma-like tumor	Mutsumi Takadera	Japan
		EPEB-P-19	EPEN-14	Generation of a C11orf95-RELA fusion targeting antibody as a diagnostic tool for supratentorial ependymoma	Lisa Ruff	UK
		EPEB-P-20	EPEN-44	Extracellular vesicles of supratentorial ependymoma RELA mediate interactions with cells of the tumor microenvironment	Kendra Maass	Germany
		EPEB-P-21	EPEN-46	DNA methylation landscape of recurrent pediatric ependymoma identifies key driver events	Sibo Zhao	USA
		EPEB-P-22	EPEN-05	Clinical and genetic evolution of ependymoma exposed from a multi-recurrence girl case	Zhong-ping Chen	China
		EPEB-P-23	EPEN-47	PEDS: Pediatric ependymoma discovery study	Amy Smith	USA
	Ependymoma (clinical)	EPEC-IS-01	SPKR-19	Posterior Fossa Ependymoma (PF EPN): Reaching for Effective Therapy while exploring new Biology.	Nicholas Foreman	USA
		EPEC-O-02	EPEN-54	ACNS0831, Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years	Amy Smith	USA
		EPEC-O-03	EPEN-09	Impact of molecular subgroup on outcome for infants <12 months with intracranial ependymoma - German experience from HIT2000, Interim-2000-registry and I-HIT-MED registry	Denise Obrecht	Germany
		EPEC-O-04	EPEN-03	Long-term follow-up of AIEOP 2nd series of children and adolescent with primary intracranial (ST:supratentorial; PF: posterior fossa) ependymoma and methylation groups re-analyses	Maura Massimino	Italy
		EPEC-O-05	EPEN-06	Chemotherapy of recurrent ependymoma: long-term response only in few cases	Jonas Adolph	Germany
		EPEC-O-06	EPEN-39	Clinical stratified treatment of localized pediatric intracranial ependymoma with combined local irradiation and chemotherapy within the prospective, multicenter E-HIT trial – the molecular subgroup matters	Denise Obrecht	Germany
		EPEC-P-07	EPEN-02	Evaluation of treatment outcomes and expression of EMT-related transcription factors as novel therapeutic targets in pediatric ependymoma	Keishi Makino	Japan
		EPEC-P-08	EPEN-10	Spinal myxopapillary ependymoma and methylation-profiling: The MD Anderson Cancer Center (MDACC) experience	Sumit Gupta	USA
		EPEC-P-09	EPEN-37	Treatment outcome of recurrent ependymoma in children in Northern Egypt	Shady Fadel	Egypt
		EPEC-P-10	EPEN-36	The treatment outcome of paediatric supratentorial C11orf95-RELA fused ependymoma: A combined report from E-HIT series and Australian New Zealand Children's Haematology/Oncology Group	Chia Huan Ng	Australia
		EPEC-P-11	EPEN-45	Normalizing and facilitating genomic testing at diagnosis in pediatric ependymoma	Emily Owens Pickle	USA
		EPEC-P-12	EPEN-07	Patterns of extraneural metastases in pediatric supratentorial ependymoma: case series and review of the literature	Priya Chan	USA
		EPEC-P-13	EPEN-24	SIOP Ependymoma II: Central Ependymoma Management Advisory Group – The UK Experience	Richard Grundy	UK
		EPEC-P-14	EPEN-38	EZH2 inhibitory protein (EZH1/Cxor67) expression is highly concordant with H3K27me3 loss and is a promising surrogate marker for posterior fossa type A ependymomas	Aruna Nambirajan	India
		EPEC-P-15	EPEN-01	Multidisciplinary treatment in ependymoma	Daisuke Hirokawa	Japan
		EPEC-P-16	EPEN-49	Response of recurrent ependymoma to MEMMAT based metronomic antiangiogenic combination therapy utilizing tapered bevacizumab and maintenance therapy with celecoxib and fenofibrate	Eileen Gillan	USA
		EPEC-P-17	EPEN-50	The management and treatment of pediatric spinal cord ependymoma: Results from a collaborative international multi-institutional review	John Lucas	USA
		EPEC-P-18	EPEN-25	Exceptional clinical and imaging response to TRK-inhibition in a patient with supratentorial ependymoma harboring NTRK2 gene fusion	Ross Mangum	USA
		EPEC-P-19	EPEN-28	Novel oncogene amplification in spinal ependymoma involving the myc locus (8q24)	Margaret Shatara	USA
		EPEC-P-20	EPEN-17	Favorable outcome to intensive chemotherapy without irradiation in infantile metastatic ependymoma with a novel molecular profile: a case report	Flavia de Faria	Brazil
		EPEC-P-21	EPEN-35	Peritoneal carcinomatosis of anaplastic ependymoma: First reported case	Jonathan Schwartz	USA
		EPEC-P-22	EPEN-51	Childhood intracranial ependymoma: a multi-center retrospective analysis	Amy Smith	USA
		EPEC-P-23	EPEN-11	Ongoing response in a multiply relapsed metastatic posterior fossa ependymoma A after vorinostat and concomitant irradiation	Hamza Gorski	USA
		EPEC-P-24	EPEN-13	Primary extradural sacrococcygeal subcutaneous myxopapillary ependymoma misdiagnosed as pilonidal cyst in a 7 year-old boy: A case report	Regina Navarro-Martin del Campo	Mexico
EPEC-O-25	EPEN-53	C11orf95-RELA reprograms 3D epigenome in supratentorial ependymoma	Ching Lau	USA		